Top

Current Allergy and Asthma Reports

Published in:

01-12-2019 | Allergic Rhinitis | Allergic Skin Diseases (L Fonacier and A Wollenberg, Section Editors)

Allergen Immunotherapy and Atopic Dermatitis: the Good, the Bad, and the Unknown

Authors: Patrick Rizk, Mario Rodenas, Anna De Benedetto

Published in: Current Allergy and Asthma Reports | Issue 12/2019

Abstract

Purpose of Review

In light of the recent advancements in atopic dermatitis treatment, this review aims to summarize the utility and efficacy of allergy immunotherapy in atopic dermatitis patients. We examine its mechanism, pathophysiology, cost-efficacy, and current guidelines for clinical practice.

Recent Findings

The literature supports the use of allergy immunotherapy in atopic conditions such as allergic rhinitis and asthma but insufficient evidence exists to suggest its efficacy in atopic dermatitis. The use of allergy immunotherapy has been shown to provide long-term cost savings in both the USA and the European Union in certain populations but differences in prescribing patterns and manufacturing make it difficult to study its impact on a larger, generalizable scale.

Summary

Conflicting meta-analyses data and conclusions highlight the need for better, higher quality research to better understand allergy immunotherapy utility in atopic dermatitis.

Leung DYM, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151–60. https://doi.org/10.1016/s0140-6736(03)12193-9.CrossRefPubMed

•• Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–49. https://doi.org/10.1016/j.jaci.2016.06.010 Excellent paper summarizing the immunological mechanisms in AD pathogenesis. CrossRefPubMed

Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol. 2003;112(2):252–62.CrossRef

Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose–response study. Allergy. 2006;61(2):202–5.CrossRef

Frischmeyer-Guerrerio PA, Rasooly M, Gu WJ, Levin S, Jhamnani RD, Milner JD et al. IgE testing can predict food allergy status in patients with moderate to severe atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(4):393-+. doi:10.1016/j.anai.2019.01.001.CrossRef

Fleischer DM, Bock SA, Spears GC, Wilson CG, Miyazawa NK, Gleason MC, et al. Oral food challenges in children with a diagnosis of food allergy. J Pediatr. 2011;158(4):578–83.e1.CrossRef

Ring J, Zink A, Arents BWM, Seitz IA, Mensing U, Schielein MC, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019;33(7):1331–40. https://doi.org/10.1111/jdv.15634.CrossRefPubMed

Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J Allergy Clin Immunol. 1999;103(1):125–38. https://doi.org/10.1016/s0091-6749(99)70536-1.CrossRefPubMed

Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476–86. https://doi.org/10.1111/pai.12095.CrossRefPubMedPubMedCentral

10.

Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94. https://doi.org/10.1056/NEJMra074081.CrossRefPubMed

11.

Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526-+. https://doi.org/10.1016/j.jaad.2018.05.1241.CrossRefPubMed

12.

Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. J Allergy Clin Immunol. 1999;104(3):S123–S5. https://doi.org/10.1016/s0091-6749(99)70054-0.CrossRefPubMed

13.

Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140(3):633–43. https://doi.org/10.1016/j.jaci.2017.07.006.CrossRefPubMed

14.

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–78.CrossRef

15.

Andersen YM, Egeberg A, Ban L, Gran S, Williams HC, Francis NA, et al. Association between topical corticosteroid use and type 2 diabetes in two European population-based adult cohorts. Diabetes Care. 2019;42(6):1095–103.CrossRef

16.

Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315–27. https://doi.org/10.1056/NEJMra1011040.CrossRefPubMed

17.

Yang H, Wang J, Zhang X, Zhang Y, Qin ZL, Wang H, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis a systematic review and meta-analysis. Jama Dermatol. 2019;155(5):585–93. https://doi.org/10.1001/jamadermatol.2019.0008.CrossRefPubMedPubMedCentral

18.

Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6(1):17–26.CrossRef

19.

Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007;8(5):364–72.PubMed

20.

Jimenez JL, Punzón C, Navarro J, Muñoz-Fernández MA, Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther. 2001;299(2):753–9.PubMed

21.

Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7(10):1043–58. https://doi.org/10.2217/imt.15.69.CrossRefPubMed

22.

Holm JG, Thomsen SF. Omalizumab for atopic dermatitis: evidence for and against its use. G Ital Dermatol Venereol. 2019;154(4):480–7. https://doi.org/10.23736/s0392-0488.19.06302-8.CrossRefPubMed

23.

Kupczyk M. Future directions of application and development of allergen immunotherapy. Alergol Polska-Polish J Allergol. 2018;5(2):80–4. https://doi.org/10.5114/pja.2018.76676.CrossRef

24.

Hotze M, Baurecht H, Rodríguez E, Chapman-Rothe N, Ollert M, Fölster-Holst R, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy. 2014;69(1):132–5.CrossRef

25.

• Owens S, Liu H, Sun K, Venturanza M, Kuligowski M, Howell M, editors. Ruxolitinib cream significantly modulates inflammatory profiles of atopic dermatitis patients. J Investig Dermatol; 2019: ELSEVIER SCIENCE INC STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA. Study showing the efficacy of ruxolitinib in reducing itch, reveling novel mechanism involved in itch.

26.

Uermosi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G. IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization (vol 69, pg 338, 2014). Allergy. 2014;69(8):1118. https://doi.org/10.1111/all.12460.CrossRef

27.

•• Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6(10):761–71. https://doi.org/10.1038/nri1934 Detailed overview of mechanisms of allergy immunotherapy in atopic disorders. CrossRefPubMed

28.

Stanic B, van de Veen W, Wirz OF, Ruckert B, Morita H, Sollner S, et al. IL-10-overexpressing B cells regulate innate and adaptive immune responses. J Allergy Clin Immunol. 2015;135(3):771–U299. https://doi.org/10.1016/j.jaci.2014.07.041.CrossRefPubMed

29.

Frankland A. High and low dosage pollen extract treatment in summer hay fever and asthma. Allergy. 1955;9(3):183–7.CrossRef

30.

Patel P, Salapatek AMF. Pollinex((R)) Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines. 2006;5(5):617–29. https://doi.org/10.1586/14760584.5.5.617.CrossRefPubMed

31.

Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97(2):141–8. https://doi.org/10.1016/s1081-1206(10)60004-x.CrossRefPubMed

32.

Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120(1):164–70. https://doi.org/10.1016/j.jaci.2007.04.008.CrossRefPubMed

33.

Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. J Allergy Clin Immunol. 2014;2(2):156–60.e2.CrossRef

34.

Sade K, Berkun Y, Dolev Z, Shalit M, Kivity S. Knowledge and expectations of patients receiving aeroallergen immunotherapy. Ann Allergy Asthma Immunol. 2003;91(5):444–8.CrossRef

35.

Abramowicz M, Kruszewski J, Chcialowski A. Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials. Postepy Dermatologii I Alergologii. 2018;35(6):620–5. https://doi.org/10.5114/ada.2018.77614.CrossRefPubMedPubMedCentral

36.

Incorvaia C, Berto P, Ariano R, Elia R, Frati F. Cost-effectiveness of allergen immunotherapy. J Aller Ther S. 2012;6:2.

37.

Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol. 2005;33(6):296–302.CrossRef

38.

Hankin CS, Cox L, Lang D, Levin A, Gross G, Eavy G, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol. 2008;121(1):227–32.CrossRef

39.

Berto P, Bassi M, Incorvaia C, Frati F, Puccinelli P, Giaquinto C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol. 2005;37(8):303–8.PubMed

40.

Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. Jama. 2005;294(20):2618–22.CrossRef

41.

Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX (R)) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy. 2007;37(5):772–9. https://doi.org/10.1111/j.1365-2222.2007.02706.x.CrossRefPubMed

42.

Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX (R) for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med. 2007;101(9):1885–94. https://doi.org/10.1016/j.rmed.2007.05.003.CrossRefPubMed

43.

Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014;14(4):363–70. https://doi.org/10.1097/aci.0000000000000084.CrossRefPubMed

44.

•• Mahler V, Esch RE, Kleine-Tebbe J, Lavery WJ, Plunkett G, Vieths S, et al. Understanding differences in allergen immunotherapy products and practices in North America and Europe. J Allergy Clin Immunol. 2019;143(3):813–30. https://doi.org/10.1016/j.jaci.2019.01.024 Provides an in-depth discussion of AIT in US vs. EU regulations, diagnostics, and practice patterns. CrossRefPubMed

45.

Slater JE, Menzies SL, Bridgewater J, Mosquera A, Zinderman CE, Ou AC, et al. The US Food and Drug Administration review of the safety and effectiveness of nonstandardized allergen extracts. J Allergy Clin Immunol. 2012;129(4):1014–9.CrossRef

46.

Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: a practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28–54.CrossRef

47.

Roberts G, Pfaar O, Akdis C, Ansotegui I, Durham S, Gerth van Wijk R, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–98.CrossRef

48.

Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo J Int. 2014;23(8):282–319.CrossRef

49.

Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. Jama. 2016;315(16):1715–25.CrossRef

50.

Sánchez Caraballo JM, Cardona VR. Clinical and immunological changes of immunotherapy in patients with atopic dermatitis: randomized controlled trial. ISRN Allergy. 2012;2012.

51.

• Tam HH, Calderon MA, Manikam L, Nankervis H, Núñez IG, Williams HC, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review. Allergy. 2016;71(9):1345–56. https://doi.org/10.1111/all.12932 Recent meta-analysis on AIT efficacy in AD.CrossRefPubMed

52.

Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110–7.CrossRef

53.

•• Ridolo E, Martignago I, Riario-Sforza GG, Incorvaia C. Allergen immunotherapy in atopic dermatitis. Expert Rev Clin Immunol. 2018;14(1):61–8 Great source of updated guidelines and recommendations for AIT. CrossRef

54.

• Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2. https://doi.org/10.1016/j.anai.2017.10.039 Updates on AD management with practical information based on disease severity and impact on quality of life. CrossRefPubMed

55.

Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis–a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology Guidelines. Alergol Polska-Polish J Allergol. 2017;4(4):158–68.CrossRef

Title: Allergen Immunotherapy and Atopic Dermatitis: the Good, the Bad, and the Unknown
Authors: Patrick Rizk
Mario Rodenas
Anna De Benedetto
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Allergic Rhinitis
Bronchial Asthma
Atopic Dermatitis
Published in: Current Allergy and Asthma Reports / Issue 12/2019
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-019-0893-z

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Allergen Immunotherapy and Atopic Dermatitis: the Good, the Bad, and the Unknown

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2019

Prevention of Non-peanut Food Allergies

Correction to: Basophil Activation Test: Old and New Applications in Allergy

Occupational Rhinitis: Classification, Diagnosis, and Therapeutics

The Impact of Ambient Environmental Exposures to Microbial Products on Asthma Outcomes from Birth to Childhood

Epigenetics in Asthma

Biomarkers in Food Allergy Immunotherapy